rhTPO plus cyclosporine for transfusion-dependent aplastic anemia
Treatments studied
Part of Blood & lymphatic clinical trials.
This trial tests whether adding a platelet-boosting medicine (rhTPO) to a standard immune-suppressing drug (cyclosporine) works better than cyclosporine alone for people with aplastic anemia who need regular blood transfusions. The goal is to improve blood counts and reduce the need for transfusions.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have a type of aplastic anemia that needs regular blood transfusions (at least every 8 weeks for 4 months or more) or very low blood cell counts.
- You have not already been treated with platelet-boosting drugs (like eltrombopag or romiplostim) or other strong immune-suppressing medicines.
- You are not able or willing to have a stem cell transplant.
- Your liver, kidney, and other organs are working fairly well, and you have no serious heart, lung, or blood-clot problems.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests combining a drug called romiplostim (a bone marrow stimulant) with standard immunosuppressive therapy as a first treatment for severe aplastic anemia. It aims to improve blood cell counts and reduce the need for transfusions.
This study tests a drug called romiplostim to see if it can help people with non-severe aplastic anemia (NSAA) who still need regular blood transfusions even after standard treatments. Romiplostim works by stimulating your body to make more blood cells, which may reduce your need for transfusions.
This trial tests a “half-matched” stem cell transplant for children and teens with severe aplastic anemia when a fully matched donor isn’t available. It may help rebuild blood-making cells after prior treatments did not work well enough.
This trial tests if sirolimus (an immune-suppressing drug) works better than current treatments for aplastic anemia patients who did not improve or had side effects from cyclosporin. It aims to find a new option to help your body make more blood cells.
This trial tests a lower dose of the chemotherapy drug cyclophosphamide combined with standard immune-suppressing medicines for people with newly diagnosed severe aplastic anemia. The goal is to see if this approach works as well as the usual treatment but with fewer side effects.
This trial tests if rhTPO (a protein that boosts platelet production) can help collect enough stem cells for your own stem cell transplant. It is for people with acute leukemia who are in remission with no detectable cancer cells left.
Hear when a new Aplastic Anemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.